Identification of potential hub genes linked to immune and metabolic alterations in postoperative systemic inflammatory dysregulation

Frontiers in Immunology, 2023 · DOI: 10.3389/fimmu.2023.1238774 · Published: September 8, 2023

Simple Explanation

Postoperative systemic inflammatory dysregulation (PSID) involves interconnected immune and metabolic abnormalities. This study aims to identify the key genes, or 'hub genes', responsible for these interconnections. The researchers analyzed gene expression in blood cells from patients with and without PSID after major abdominal surgery, exploring the biological functions of these genes and the correlations between immune-related and metabolism-related genes. The study identified several hub genes, including CD28, CD40LG, MAPK14, and S100A12, that play a critical role in the interaction between immune and metabolic changes in PSID. These findings provide insights for potential clinical treatments.

Study Duration

Not specified

Participants

46 patients (21 with PSID, CRP > 250 mg/L; 25 controls, CRP < 75 mg/L)

Evidence Level

Original Research

Key Findings

1
Identified 512 upregulated and 254 downregulated DEGs in patients with PSID compared with controls, significantly associated with immune- and metabolism-related biological processes and pathways.
2
Correlation analyses revealed a close association between irDEGs and mrDEGs, suggesting a strong link between immunity and metabolism in PSID patients.
3
CD28, CD40LG, MAPK14, and S100A12 were identified as hub genes among both immune- and metabolism-related genes, playing a critical role in the interaction between alterations in immunity and metabolism in PSID.

Research Summary

This study comprehensively analyzed gene expression in patients with PSID after major abdominal surgery to identify hub genes associated with immune and metabolic alterations. The analysis revealed significant alterations in immune and metabolic processes, with a close correlation between immune-related and metabolism-related genes. Key hub genes, including CD28, CD40LG, MAPK14, and S100A12, were identified as crucial links between immune and metabolic changes in PSID, providing potential targets for clinical treatment.

Practical Implications

Diagnostic Biomarkers

The identified hub genes, particularly CD28, CD40LG, MAPK14, and S100A12, can serve as potential diagnostic biomarkers for PSID, enabling early detection and intervention.

Therapeutic Targets

Targeting these hub genes may offer novel therapeutic strategies to modulate immune and metabolic interactions, reducing the risk of postoperative complications.

Personalized Medicine

Understanding the genetic characteristics and biological alterations in PSID can pave the way for personalized treatment approaches tailored to individual patient profiles.

Study Limitations

1
The study is based on a single public RNA-seq dataset, limiting the generalizability of the findings.
2
Further validation is needed in larger, independent cohorts to confirm the diagnostic and therapeutic potential of the identified hub genes.
3
The molecular mechanisms underlying the interactions between the identified hub genes and immune-metabolic dysregulation in PSID require further investigation.

Your Feedback

Was this summary helpful?

Back to Immunology